De Burlo Group’s ResMed RMD Stock Holding History

De Burlo Group’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,200	Closed	-$252K	–	216
2022 Q2	$252K	Buy	+1,200	New	+$255K	0.07%	72

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

De Burlo Group's RMD Position: Q3 2022 in Review

De Burlo Group sold out of ResMed (RMD) in Q3 2022, closing a stake of 1,200 shares — an estimated $252K sold.

De Burlo Group first reported a position in RMD in Q2 2022 and held it in 1 quarter. The position peaked at $252K in Q2 2022. 667 funds tracked by Wall St. Rank hold RMD as of Q3 2022.

De Burlo Group reported no remaining ResMed position as of Q3 2022 after selling out during the quarter.
De Burlo Group sold 1,200 ResMed shares in Q3 2022, an estimated $252K.
De Burlo Group first reported a position in ResMed in Q2 2022 and held it in 1 quarter.
De Burlo Group's ResMed position peaked at $252K in Q2 2022.
667 funds tracked by Wall St. Rank held ResMed as of Q3 2022.

Based on De Burlo Group's 13F filing for Q3 2022, filed 14 Nov 2022.